About TG Therapeutics (NASDAQ:TGTX)
TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia. The company also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies. In addition, it develops a pre-clinical program to develop interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors; bromodomain and extra terminal (BET) inhibitor program for cancer treatment; and anti-PD-L1 and anti-GITR antibody research programs that are in pre-clinical development stage in the field of hematological malignancies. The company has license agreements with LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, and Ildong Pharmaceutical Co. Ltd. for the development and commercialization of TG-1101 (ublituximab); Rhizen Pharmaceuticals, SA for the development and commercialization of TGR-1202; Ligand Pharmaceuticals Incorporated for the development and commercialization of IRAK4 inhibitor technology; Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs; and Jubilant Biosys for the development and commercialization of BET inhibitor program. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TGTX
CUSIPN/A
Phone212-554-4484
Debt
Debt-to-Equity RatioN/A
Current Ratio3.34%
Quick Ratio3.34%
Price-To-Earnings
Trailing P/E Ratio-7.36
Forward P/E Ratio-8.36
P/E GrowthN/A
Sales & Book Value
Annual Sales$150,000.00
Price / Sales7,079.33
Cash FlowN/A
Price / CashN/A
Book Value$0.95 per share
Price / Book14.79
Profitability
EPS (Most Recent Fiscal Year)($1.91)
Net Income$-118,470,000.00
Net Margins-77,945.40%
Return on Equity-145.58%
Return on Assets-111.88%
Miscellaneous
Employees75
Outstanding Shares75,580,000
TG Therapeutics (NASDAQ:TGTX) Frequently Asked Questions
What is TG Therapeutics' stock symbol?
TG Therapeutics trades on the NASDAQ under the ticker symbol "TGTX."
How were TG Therapeutics' earnings last quarter?
TG Therapeutics, Inc (NASDAQ:TGTX) posted its quarterly earnings data on Thursday, March, 8th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, hitting the Zacks' consensus estimate of ($0.46). The biopharmaceutical company earned $0.04 million during the quarter, compared to the consensus estimate of $0.04 million. TG Therapeutics had a negative return on equity of 145.58% and a negative net margin of 77,945.40%. View TG Therapeutics' Earnings History.
What price target have analysts set for TGTX?
6 equities research analysts have issued 12 month price targets for TG Therapeutics' shares. Their predictions range from $23.00 to $33.00. On average, they anticipate TG Therapeutics' stock price to reach $27.75 in the next twelve months. View Analyst Ratings for TG Therapeutics.
What are Wall Street analysts saying about TG Therapeutics stock?
Here are some recent quotes from research analysts about TG Therapeutics stock:
- 1. Raymond James analysts commented, "We are reiterating our Strong Buy rating on TG Therapeutics. At the 2018 American Association of Cancer Research (AACR) annual meeting, the company presented a poster featuring preclinical data of a BET inhibitor (TG-1601), which, based on our analysis of the data, supports clinical evaluation of this compound in combination with the company’s other pipeline products. Separately, in the PI3K delta world, Incyte presented clinical data of its PI3K delta inhibitor (INCB050465) in combination with pembrolizumab (Pembro) in solid tumors, demonstrating that PI3K delta inhibition appeared to synergize with PD-1 blockade. We view the totality of the clinical findings as great news for TG Therapeutics given that the company may have a best-in-class PI3K delta inhibitor, which could also demonstrate synergistic clinical effects when combined with a PD-1/PD-L1 inhibitor." (4/19/2018)
- 2. According to Zacks Investment Research, "TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York. " (2/16/2018)
- 3. HC Wainwright analysts commented, "TG Announces Global License Agreement With Jiangsu Hengrui Medicine for Development of Novel BTK Inhibitors TG licenses novel BTK inhibitors that demonstrate superior selectivity to BTK in comparison to ibrutinib in the preclinical setting. On the morning of January 8, TG Therapeutics announced that it has entered into an exclusive global license agreement with Jiangsu Hengrui Medicine, pursuant to which TG will obtain worldwide rights, excluding Asia but including Japan, for the development of Hengrui’s BTK inhibitor program. The program includes TG-1701 and TG-1702, both of which are orally-available, covalently-bound BTK inhibitors." (1/8/2018)
Are investors shorting TG Therapeutics?
TG Therapeutics saw a drop in short interest during the month of March. As of March 15th, there was short interest totalling 14,021,571 shares, a drop of 13.0% from the February 28th total of 16,118,224 shares. Based on an average trading volume of 1,556,466 shares, the days-to-cover ratio is presently 9.0 days. Currently, 24.9% of the shares of the company are sold short.
Who are some of TG Therapeutics' key competitors?
Some companies that are related to TG Therapeutics include Taro Pharmaceutical Industries (TARO), Loxo Oncology (LOXO), FibroGen (FGEN), GW Pharmaceuticals (GWPH), Advanced Accelerator Application (AAAP), Blueprint Medicines (BPMC), Ligand Pharmaceuticals (LGND), Array BioPharma (ARRY), Tesaro (TSRO), Ultragenyx Pharmaceutical (RARE), Emergent BioSolutions (EBS), Amicus Therapeutics (FOLD), Ascendis Pharma (ASND), Evotec A.G. (EVTCY) and Clovis Oncology (CLVS).
Who are TG Therapeutics' key executives?
TG Therapeutics' management team includes the folowing people:
- Mr. Michael S. Weiss, Exec. Chairman, Chief Exec. Officer and Pres (Age 52)
- Mr. Sean A. Power CPA, Chief Financial Officer, Corp. Sec. and Treasurer (Age 36)
- Jenna Bosco, Director of Investor Relations
Has TG Therapeutics been receiving favorable news coverage?
Press coverage about TGTX stock has been trending somewhat positive recently, according to Accern. The research group rates the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. TG Therapeutics earned a media sentiment score of 0.11 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 47.96 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
How do I buy shares of TG Therapeutics?
Shares of TGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is TG Therapeutics' stock price today?
One share of TGTX stock can currently be purchased for approximately $14.05.
How big of a company is TG Therapeutics?
TG Therapeutics has a market capitalization of $1.09 billion and generates $150,000.00 in revenue each year. The biopharmaceutical company earns $-118,470,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. TG Therapeutics employs 75 workers across the globe.
How can I contact TG Therapeutics?
TG Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company can be reached via phone at 212-554-4484 or via email at [email protected]
MarketBeat Community Rating for TG Therapeutics (TGTX)
MarketBeat's community ratings are surveys of what our community members think about TG Therapeutics and other stocks. Vote "Outperform" if you believe TGTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TGTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
TG Therapeutics (NASDAQ:TGTX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for TG Therapeutics in the last 12 months. Their average twelve-month price target is $27.75, suggesting that the stock has a possible upside of 97.51%. The high price target for TGTX is $33.00 and the low price target for TGTX is $23.00. There are currently 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $27.75 | $27.75 | $27.1875 | $26.75 |
| Price Target Upside: | 97.51% upside | 68.18% upside | 184.69% upside | 122.92% upside |
TG Therapeutics (NASDAQ:TGTX) Consensus Price Target History
TG Therapeutics (NASDAQ:TGTX) Analyst Ratings History
Show:
(Data available from 4/24/2016 forward)
TG Therapeutics (NASDAQ:TGTX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
TG Therapeutics (NASDAQ TGTX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 16.70%
Institutional Ownership Percentage: 47.35%
TG Therapeutics (NASDAQ TGTX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 1/2/2018 | Sean A Power | CFO | Sell | 32,006 | $8.50 | $272,051.00 | 517,464 |  |
| 6/19/2017 | Sean A Power | CFO | Sell | 59,976 | $11.09 | $665,133.84 | 477,464 | |
| 4/11/2017 | William James Kennedy | Director | Sell | 8,548 | $10.27 | $87,787.96 | | |
| 4/4/2017 | Laurence N. Charney | Director | Sell | 7,000 | $11.17 | $78,190.00 | | |
| 1/4/2017 | Sean A. Power | CFO | Sell | 8,816 | $4.55 | $40,112.80 | | |
| 4/18/2016 | Sean A Power | CFO | Sell | 10,000 | $10.12 | $101,200.00 | 466,682 | |
| 1/5/2016 | Sean A Power | CFO | Sell | 22,790 | $11.21 | $255,475.90 | 476,682 | |
| 7/8/2015 | William James Kennedy | Director | Sell | 17,000 | $17.08 | $290,360.00 | | |
| 7/1/2015 | Sean A Power | CFO | Sell | 50,054 | $16.46 | $823,888.84 | | |
| 4/2/2015 | Sean A Power | CFO | Sell | 23,800 | $15.50 | $368,900.00 | | |
| 1/7/2015 | Sean A Power | CFO | Sell | 66,401 | $16.40 | $1,088,976.40 | | |
| 1/5/2015 | Sean A Power | CFO | Sell | 54,057 | $16.40 | $886,534.80 | | |
| 12/16/2014 | Michael S Weiss | Major Shareholder | Sell | 210,618 | $16.44 | $3,462,559.92 | | |
| 12/16/2014 | Sean A Power | CFO | Sell | 38,041 | $16.44 | $625,394.04 | | |
| 12/11/2013 | Michael Weiss | major shareholder | Buy | 10,000 | $3.43 | $34,300.00 | 7,839,471 | |
(Data available from 1/1/2013 forward)
TG Therapeutics (NASDAQ TGTX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | TG Therapeutics (TGTX) Announces Preclinical Data Presentation on the Company’s BET Inhibitor, TG-1601, at AACR
www.streetinsider.com - April 19 at 4:49 PM |
 | Raymond James Reiterates "Buy" Rating for TG Therapeutics (TGTX)
www.americanbankingnews.com - April 19 at 11:46 AM |
 | TG Therapeutics, Inc. Announces Preclinical Data Presentation on the Company's BET Inhibitor, TG-1601, at the 2018 ...
globenewswire.com - April 19 at 9:31 AM |
| TG Therapeutics (TGTX) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 18 at 2:58 PM |
 | TG Therapeutics, Inc. Announces Preclinical Data Presentation on the Company’s BET Inhibitor, TG-1601, at the 2018 American Association for Cancer Research (AACR) Annual Meeting
finance.yahoo.com - April 18 at 9:35 AM |
| Analysts Anticipate TG Therapeutics Inc (TGTX) Will Announce Quarterly Sales of $40,000.00
www.americanbankingnews.com - April 15 at 3:45 AM |
 | Q2 2018 Biotech Catalyst Watchlist: Phase 3 Clinical Trials
seekingalpha.com - April 13 at 4:43 PM |
| Analysts Expect TG Therapeutics Inc (TGTX) Will Post Earnings of -$0.46 Per Share
www.americanbankingnews.com - April 13 at 1:10 PM |
| TG Therapeutics Inc (TGTX) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - April 11 at 5:43 PM |
| BidaskClub Lowers TG Therapeutics (TGTX) to Sell
www.americanbankingnews.com - April 10 at 3:25 PM |
| TG Therapeutics' (TGTX) Buy Rating Reaffirmed at SunTrust Banks
www.americanbankingnews.com - April 8 at 10:08 AM |
| TG Therapeutics, Inc. to Present at the Needham 17th Annual Healthcare Conference
finance.yahoo.com - April 3 at 9:26 AM |
| TG Therapeutics (TGTX) Raised to Buy at ValuEngine
www.americanbankingnews.com - April 2 at 11:28 PM |
| Edited Transcript of TGTX earnings conference call or presentation 8-Mar-18 1:30pm GMT
finance.yahoo.com - April 1 at 9:19 AM |
| TG Therapeutics (TGTX) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 30 at 9:17 AM |
| $40,000.00 in Sales Expected for TG Therapeutics Inc (TGTX) This Quarter
www.americanbankingnews.com - March 29 at 4:54 AM |
| TG Therapeutics Inc (TGTX) Sees Large Decline in Short Interest
www.americanbankingnews.com - March 29 at 2:21 AM |
 | The 7 Best Stocks From Each Sector of Q1
investorplace.com - March 28 at 4:38 PM |
| HC Wainwright Reiterates "Buy" Rating for TG Therapeutics (TGTX)
www.americanbankingnews.com - March 28 at 12:58 PM |
| TG Therapeutics (TGTX) Downgraded to "Hold" at BidaskClub
www.americanbankingnews.com - March 28 at 11:04 AM |
| TG Therapeutics (TGTX) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - March 26 at 10:59 PM |
| TG Therapeutics (TGTX) Upgraded at BidaskClub
www.americanbankingnews.com - March 24 at 12:28 PM |
| TG Therapeutics' (TGTX) CEO Michael Weiss on Q4 2017 Results - Earnings Call Transcript
seekingalpha.com - March 18 at 9:39 AM |
| TG Therapeutics Inc (TGTX) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 17 at 5:30 PM |
| TG Therapeutics (TGTX) Announces Preclinical Data Presentation at AACR
www.streetinsider.com - March 16 at 10:04 AM |
| TG Therapeutics, Inc. Announces Preclinical Data Presentation at the 2018 American Association for Cancer Research (AACR) Annual Meeting
finance.yahoo.com - March 15 at 10:19 AM |
| Short Interest in TG Therapeutics Inc (TGTX) Declines By 15.0%
www.americanbankingnews.com - March 12 at 1:24 AM |
| TG Therapeutics (TGTX) Posts Earnings Results, Hits Estimates
www.americanbankingnews.com - March 9 at 6:52 PM |
| TG Therapeutics (TGTX) PT Raised to $27.00
www.americanbankingnews.com - March 9 at 9:18 AM |
| TG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2017 Financial Results and Business Update
finance.yahoo.com - March 8 at 10:31 AM |
| TG Therapeutics, Inc. to Host Conference Call on Fourth Quarter and Year-End 2017 Financial Results and Business Update
finance.yahoo.com - March 6 at 9:34 AM |
| Senzar Asset Management LLC Boosts Position in TG Therapeutics Inc (TGTX)
www.americanbankingnews.com - March 5 at 3:45 PM |
| Zacks: Brokerages Expect TG Therapeutics Inc (TGTX) Will Announce Earnings of -$0.46 Per Share
www.americanbankingnews.com - February 21 at 3:18 PM |
| TG Therapeutics, Inc. Announces Publication of Clinical Data from the Phase 1 First-in-Human Trial of Umbralisib in The Lancet Oncology
finance.yahoo.com - February 21 at 9:50 AM |
| TG Therapeutics Inc (TGTX) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - February 20 at 5:32 PM |
| Protagonist Therapeutics (PTGX) and TG Therapeutics (TGTX) Head to Head Survey
www.americanbankingnews.com - February 18 at 1:46 PM |
| TG Therapeutics (TGTX) Upgraded at Zacks Investment Research
www.americanbankingnews.com - February 16 at 7:42 PM |
| Equities Analysts Set Expectations for TG Therapeutics Inc's FY2018 Earnings (TGTX)
www.americanbankingnews.com - February 15 at 10:56 AM |
| TG Therapeutics Inc Forecasted to Earn FY2022 Earnings of $1.12 Per Share (TGTX)
www.americanbankingnews.com - February 14 at 4:12 PM |
| TG Therapeutics: Further Appreciation In 2018 Likely - Seeking Alpha
seekingalpha.com - February 6 at 6:25 AM |
| TG Therapeutics Inc (TGTX) Expected to Post Earnings of -$0.46 Per Share
www.americanbankingnews.com - February 4 at 3:20 PM |
| TG Therapeutics (TGTX) Upgraded by ValuEngine to Hold
www.americanbankingnews.com - February 4 at 11:46 AM |
| TG Therapeutics (TGTX) Announces Updated Results from Ongoing ... - StreetInsider.com
www.streetinsider.com - February 2 at 3:26 PM |
| TG Therapeutics, Inc. Announces Updated Results from the Ongoing Phase 2 Study of Ublituximab (TG-1101) in Patients with Multiple Sclerosis at the Third Annual ACTRIMS Forum 2018
finance.yahoo.com - February 2 at 3:26 PM |
| TG Therapeutics (TGTX) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - January 30 at 8:18 AM |
| TG Therapeutics Inc (TGTX) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - January 26 at 5:38 PM |
| TG Therapeutics, Inc. Announces Data Presentation at the ... - GlobeNewswire (press release)
globenewswire.com - January 24 at 3:28 PM |
| TG Therapeutics, Inc. Announces Data Presentation at the Upcoming Third Annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2018
finance.yahoo.com - January 24 at 9:52 AM |
| TG Therapeutics Inc (TGTX) Expected to Announce Quarterly Sales of $40,000.00
www.americanbankingnews.com - January 20 at 4:56 AM |
| TG Therapeutics (TGTX) Rating Reiterated by B. Riley
www.americanbankingnews.com - January 17 at 1:34 PM |
TG Therapeutics (NASDAQ:TGTX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
TG Therapeutics (NASDAQ:TGTX) Income Statement, Balance Sheet and Cash Flow Statement
TG Therapeutics (NASDAQ TGTX) Stock Chart for Tuesday, April, 24, 2018
Loading chart…
